Becton Dickinson and Company

Healthcare
$251.82
+2.68 (1.08%) 1D
1D
1W
1M
1Y
3Y
5Y

Performance

Open PricePrev. CloseVolumeAvg. Volume
$249.29$249.141,231,4341,117,287

Fundamentals

Market Cap$71.35B
P/B Ratio2.8
P/E Ratio42.2
Enterprise Value$86.26B
Div. Yield1.46%
Book Value89.22
EPS(TTM)0.94
ROENA
Understand Fundamentals

About the Company

Commonly known as BD, Becton Dickinson and Company is a multinational medical technology firm. The company manufactures and sells reagents, medical devices and instrument systems, with an aim to discover, diagnose and deliver care. It has three worldwide segments, namely BD Life Sciences, BD Medical and BD Interventional. Its consumers include the healthcare industry, researchers, medical institutions, clinical laboratories, as well as the general public across the globe. With its corporate headquarters in New Jersey, United States, the company has operations in several countries worldwide. Its global offices are located in Australia, Norway, South Korea, Kuwait, Laos, Sweden, South Africa, UAE, Germany, India, France, Russia, Mexico, among others. Becton Dickinson and Company shares trade on the New York Stock Exchange (NYSE) under the ticker symbol BDX. BDX stock is also an S&P 500 component. The company was founded in 1897 in East Rutherford, New Jersey. BDX made its first acquisition in 1904 when it bought the Philadelphia Surgical Company. This acquisition, and several others that followed it, contributed greatly to its product expansion as well as manufacturing capabilities. It went public in 1972 and entered the list of Fortune 500 companies in 1970. In 1981, the company surpassed $1 billion in sales and continued its international expansion. BDX partnered with UNICEF to launch the BD Uniject™ injection in 2002, to accelerate the elimination of maternal and neonatal tetanus. In 2005, the company joined the International AIDS Vaccine Initiative (IAVI), a non-profit organisation that works on the development of HIV vaccine throughout the world. In 2011, BDX received CEO Cancer Gold Standard™ accreditation, for its commitment to reducing the risk of cancer. It accepted the Champion for Change Award by Practice Greenhealth in 2016, for its environmental excellence. Its revenues reached $2.97 billion in 2017. The same year, the company invested 6.3% of its total revenues in R&D in order to continue its development of innovative products. As a leading medical technology company in 2019, BDX deployed its resources and expertise to combat the pandemic. Additionally, it contributed $1.1 million towards global Covid-19 response efforts. As of 2020, BDX ranked 344th on Forbes 2000 and 197th on the list of Fortune 500. Forbes also included it in its rankings of Just Companies, World’s Best Employers, Best Employers for Veterans as well as Best Employers for Diversity. Its net worth stood at $70.38 billion as on November 16th, 2020.;
OrganisationBecton Dickinson and Company
IndustryMedical Instruments & Supplies
HeadQuartersFranklin Lakes, NJ

Company Financials

*All values are in Million $
No Graph Data To Display
Quarterly
Yearly

Similar Stocks

COMPANYMARKET PRICECLOSE PRICEMARKET CAP
Want to invest in US Stocks?
Signup with Groww to get started
Login / Register
ⓒ 2016-2023 Groww. All rights reserved, Built with in India
MOST POPULAR ON GROWWVERSION - 3.6.9
STOCK MARKET INDICES:  S&P BSE SENSEX |  S&P BSE 100 |  NIFTY 100 |  NIFTY 50 |  NIFTY MIDCAP 100 |  NIFTY BANK |  NIFTY NEXT 50
MUTUAL FUNDS COMPANIES:  ICICI PRUDENTIAL |  HDFC |  NIPPON INDIA |  ADITYA BIRLA SUN LIFE |  SBI |  UTI |  FRANKLIN TEMPLETON |  KOTAK MAHINDRA |  IDFC |  DSP |  AXIS |  TATA |  L&T |  SUNDARAM |  PGIM |  INVESCO |  LIC |  JM FINANCIAL |  BARODA PIONEER |  CANARA ROBECO |  HSBC |  IDBI |  INDIABULLS |  MOTILAL OSWAL |  BNP PARIBAS |  MIRAE ASSET |  PRINCIPAL |  BOI AXA |  UNION KBC |  TAURUS |  EDELWEISS |  NAVI |  MAHINDRA |  QUANTUM |  PPFAS |  IIFL |  Quant |  SHRIRAM |  SAHARA |  ITI